- Home
- GPRK vs CKPT Comparison
GPRK vs CKPT Comparison
Compare GPRK & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRK
- CKPT
- Stock Information
- Founded
- GPRK 2002
- CKPT 2014
- Country
- GPRK Colombia
- CKPT United States
- Employees
- GPRK N/A
- CKPT N/A
- Industry
- GPRK Oil & Gas Production
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- GPRK Energy
- CKPT Health Care
- Exchange
- GPRK Nasdaq
- CKPT Nasdaq
- Market Cap
- GPRK 350.4M
- CKPT 335.9M
- IPO Year
- GPRK N/A
- CKPT 2017
- Fundamental
- Price
- GPRK $7.13
- CKPT $4.15
- Analyst Decision
- GPRK Buy
- CKPT Buy
- Analyst Count
- GPRK 1
- CKPT 3
- Target Price
- GPRK $11.00
- CKPT $4.33
- AVG Volume (30 Days)
- GPRK 798.1K
- CKPT 921.1K
- Earning Date
- GPRK 05-07-2025
- CKPT 05-23-2025
- Dividend Yield
- GPRK 8.23%
- CKPT N/A
- EPS Growth
- GPRK N/A
- CKPT N/A
- EPS
- GPRK 1.54
- CKPT N/A
- Revenue
- GPRK $630,738,000.00
- CKPT $41,000.00
- Revenue This Year
- GPRK N/A
- CKPT $102,182.93
- Revenue Next Year
- GPRK $13.99
- CKPT $351.71
- P/E Ratio
- GPRK $4.41
- CKPT N/A
- Revenue Growth
- GPRK N/A
- CKPT N/A
- 52 Week Low
- GPRK $5.66
- CKPT $1.47
- 52 Week High
- GPRK $11.72
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- GPRK 55.15
- CKPT 67.10
- Support Level
- GPRK $6.54
- CKPT $4.02
- Resistance Level
- GPRK $7.00
- CKPT $4.17
- Average True Range (ATR)
- GPRK 0.36
- CKPT 0.03
- MACD
- GPRK 0.08
- CKPT -0.01
- Stochastic Oscillator
- GPRK 92.17
- CKPT 76.92
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.